Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Net Cash Flow (2016 - 2025)

Abeona Therapeutics has reported Net Cash Flow over the past 15 years, most recently at -$4.8 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$4.8 million for Q4 2025, down 162.7% from a year ago — trailing twelve months through Dec 2025 was $54.7 million (up 516.19% YoY), and the annual figure for FY2025 was $54.7 million, up 516.19%.
  • Net Cash Flow for Q4 2025 was -$4.8 million at Abeona Therapeutics, up from -$80.7 million in the prior quarter.
  • Over the last five years, Net Cash Flow for ABEO hit a ceiling of $147.6 million in Q2 2025 and a floor of -$80.7 million in Q3 2025.
  • Median Net Cash Flow over the past 5 years was $296000.0 (2022), compared with a mean of $3.4 million.
  • Peak annual rise in Net Cash Flow hit 991.78% in 2024, while the deepest fall reached 1135.96% in 2024.
  • Abeona Therapeutics' Net Cash Flow stood at -$5.9 million in 2021, then skyrocketed by 158.78% to $3.5 million in 2022, then skyrocketed by 180.17% to $9.8 million in 2023, then dropped by 21.82% to $7.6 million in 2024, then tumbled by 162.7% to -$4.8 million in 2025.
  • The last three reported values for Net Cash Flow were -$4.8 million (Q4 2025), -$80.7 million (Q3 2025), and $147.6 million (Q2 2025) per Business Quant data.